GlycoMimetics Banner Image

GlycoMimetics has reached its limit for free report views

Work for GlycoMimetics? Upgrade Your Profile and unlock all your annual reports.


  • Ticker GLYC
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
GlycoMimetics Logo Image
  • 11-50 Employees
  • Based in Rockville, Maryland
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cellMore disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region.

Most Recent Annual Report

GlycoMimetics MOST RECENT 2020 Annual Report and Form 10K

Report Locked. GlycoMimetics has reached its limit for free report views.

Older/Archived Annual Reports